The increased cash runway reduces near-term dilution risk, but the growing net loss indicates continued burn rate. Monitor upcoming FDA submission in Q2 2026 for PH-762 as the next catalyst.
Price Chart
Executive Summary
Phio Pharmaceuticals reported its 2025 financial results, highlighting a successful year with completion of the PH-762 Phase 1b trial, $23.7 million in net proceeds from financings and warrant exercises, and an extended cash runway into the first half of 2027. The company reported a net loss of $8.7 million for 2025, up from $7.2 million in 2024, due to increased R&D and G&A spending.
Key Financial Metrics
Key Facts
- Completed Phase 1b dose-escalation trial for lead candidate PH-762 with favorable safety and tolerability data
- Raised $23.7 million in net proceeds during 2025 through equity financings and warrant exercises
- Cash position increased to $21.0 million at year-end 2025 from $5.4 million at year-end 2024
- Cash runway extended into the first half of 2027
- Net loss increased to $8.7 million in 2025 from $7.2 million in 2024
- R&D expenses increased 27% year-over-year; G&A expenses increased 23% year-over-year
Financial Impact
Net loss increased by $1.55 million year-over-year, while cash position grew by $15.6 million due to financings
Risk Factors
- Continuing net losses and cash burn despite recent financing
- Clinical development risks for PH-762 in later-stage trials
- Dependence on future financings or partnerships for long-term funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-007071 |
| Document: phio20251215_8k.htm | 0001437749-26-007071 |
| Document: 0001437749-26-007071-index-headers.html | 0001437749-26-007071 |
| Document: 0001437749-26-007071-index.html | 0001437749-26-007071 |
| Document: 0001437749-26-007071.txt | 0001437749-26-007071 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $1.03 $1.01 | ▼ −1.94% | ▼ −2.05% | $0.9851 (−4.36%) |
Aug 14, 2026 7w ago | DEFA14A | $1.06 $1.17 | ▲ +10.38% | ▲ +11.57% | $0.9851 (−7.07%) |
Apr 8, 2026 25w ago | 8-K | $1.25 $1.27 | ▲ +1.60% | ▼ −1.59% | $0.9851 (−21.19%) |
Apr 8, 2026 25w ago | 424B5 | $1.25 $1.27 | ▲ +1.60% | ▼ −1.59% | $0.9851 (−21.19%) |
Mar 5, 2026 30w ago | 8-K | $1.16 $1.17 | ▲ +0.86% | ▲ +2.39% | $0.9851 (−15.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access